Latest / Bloomberg Law / SEC Sued & Class Actions Over Decongestants
Transcript
- 0:00Speaker 1: A coalition representing the biggest private equity and hedge funds
- 0:04Speaker 1: is suing the Securities and Exchange Commission oversweeping new rules.
- 0:09Speaker 1: The rules will require private funds to detail quarterly fees
- 0:13Speaker 1: and expenses to investors and to perform annual audits. Firms
- 0:17Speaker 1: also will be prohibited from allowing some favorite investors to
- 0:20Speaker 1: cash out more easily than others, unless those deals are
- 0:24Speaker 1: offered to all fund investors. The coalition is asking the
- 0:28Speaker 1: Fifth Circuit Court of Appeals to vacate the rules, saying
- 0:31Speaker 1: they're arbitrary and capricious and an abuse of discretion. Joining
- 0:36Speaker 1: me is securities law expert Robert him a partner at
- 0:39Speaker 1: Tartarkrinsky and Drogan. It's a six hundred and sixty page rule.
- 0:43Speaker 1: Tell us what it provides.
- 0:45Speaker 2: The new rules that the SEC adopted were designed to
- 0:50Speaker 2: really fundamentally change the way that the private fund industry
- 0:54Speaker 2: is regulated in the United States. In its adopting release,
- 0:58Speaker 2: the SEC site they did three basic concerns that it
- 1:02Speaker 2: was trying to address, one of which was lack of
- 1:05Speaker 2: transparency in fees and charges that private funds charged to investors.
- 1:10Speaker 2: Another is conflicts of interest that the SEC was concerned
- 1:14Speaker 2: about between the advisory companies and the asset managers that
- 1:18Speaker 2: manage these funds and the investors themselves. And the third
- 1:22Speaker 2: was a lack of governance at the private fund So
- 1:25Speaker 2: in the SEC's adopting release, which is over six hundred pages,
- 1:29Speaker 2: they set out some very substantive and extensive new rules
- 1:34Speaker 2: that were designed to address these perceived shortcomings and problems
- 1:38Speaker 2: in the private fund market.
- 1:40Speaker 1: Bob, So is it because the size of the private
- 1:43Speaker 1: funds market has grown so much They now hold more
- 1:47Speaker 1: assets than commercial banks, and it's grown. According to SEC data,
- 1:51Speaker 1: gross assets under management grew one hundred and seventy one
- 1:54Speaker 1: percent from twenty twelve to twenty twenty two.
- 1:58Speaker 2: Yes, the rapid growth in the private funds market has
- 2:02Speaker 2: been one of the facts that the SEC has cited
- 2:06Speaker 2: for justification of its new rules. Right now, according to
- 2:09Speaker 2: the SEC, there's over twenty six trillion dollars in assets
- 2:13Speaker 2: under management in private funds, and the SEC used that
- 2:17Speaker 2: as one of its basis for the concerns that it's
- 2:21Speaker 2: expressed and the reason for these new extensive regulations.
- 2:26Speaker 1: This was adopted in a three to two vote along
- 2:29Speaker 1: party lines.
- 2:31Speaker 2: Yes, it's right. These new rules are very controversial, both
- 2:35Speaker 2: in the private fund industry as well as at the
- 2:38Speaker 2: Commission itself. At the time when the rules were proposed
- 2:42Speaker 2: and set for a vote at the Commission, it was
- 2:45Speaker 2: passed on a three to two vote, with two commissioners
- 2:48Speaker 2: dissenting and one of the commissioner's Commissioner Pierce, wrote a
- 2:53Speaker 2: very singing descent from the rules, saying that they were
- 2:57Speaker 2: ill conceived and that they were going to impose a
- 2:59Speaker 2: lot of costly burdens on the industry, and also criticizing
- 3:04Speaker 2: the majority of commissioners because in her view, the rules
- 3:07Speaker 2: really were not justified. Commissioner Pierce also cited the statistic
- 3:12Speaker 2: of over twenty six trillion in AUM in the industry
- 3:16Speaker 2: and said that in fact, that shows that the market
- 3:18Speaker 2: is very successful. The investors that invest in private funds
- 3:22Speaker 2: are very sophisticated institutional investors. They're advised by the world's
- 3:27Speaker 2: top law firms, and if there really was a problem
- 3:30Speaker 2: in this market, it's really hard to explain why the
- 3:33Speaker 2: private fund market would be growing so rapidly, and investors
- 3:37Speaker 2: have been enjoying significant returns and profits on their investment,
- 3:40Speaker 2: which these rules will cut into as a result of
- 3:44Speaker 2: the high cost of implementation.
- 3:47Speaker 1: These rules are watered down right from what the SEC
- 3:50Speaker 1: originally wanted.
- 3:51Speaker 2: Yes, in the proposing release that came out several months ago,
- 3:55Speaker 2: the SEC had originally proposed even more stringent rules and
- 3:59Speaker 2: stringent pro ambitions. And due to the backlash and the
- 4:02Speaker 2: comments that were submitted by investors and industry participants, the
- 4:07Speaker 2: SEC changed and when watered down some of these rules.
- 4:10Speaker 2: But the final rules were still you know, quite strong.
- 4:13Speaker 2: And I think you know what's concerned Commissioner Pierce and
- 4:17Speaker 2: others in the industry, is that really the argument here
- 4:20Speaker 2: is that the SEC overstepped its statutory authority. You know,
- 4:25Speaker 2: it's justification for adopting these new rules was based on
- 4:30Speaker 2: a provision that's the general anti fraud provision in the
- 4:33Speaker 2: Advisor's Act Statute, as well as a provision, a short
- 4:36Speaker 2: provision in dot frank that was really geared towards the
- 4:39Speaker 2: retail investors and regulating retail oriented investment funds. And the
- 4:46Speaker 2: biggest complaint of the industry they've gone to court to
- 4:49Speaker 2: challenge these rules is that the rules prohibit outright prohibit
- 4:53Speaker 2: a lot of activities and contractual terms that are very commonplace.
- 4:58Speaker 2: You know, an example of that is certain large investors
- 5:01Speaker 2: get preferred information rights, they can negotiate certain provisions with
- 5:06Speaker 2: advisors that would allow them to withdraw their funds in
- 5:10Speaker 2: a shorter lock up period than other investors. And that's
- 5:14Speaker 2: just a fundamental characteristic of the private funds market that
- 5:18Speaker 2: you can have these customized terms. But the SEC said
- 5:21Speaker 2: essentially that that can no longer happen. You can't have
- 5:24Speaker 2: negotiated terms like that.
- 5:26Speaker 1: Lead plaintiffs attorney Eugene Scalia wrote in the lawsuit quote,
- 5:30Speaker 1: the rules exceed the Commission's statutory authority, were adopted without
- 5:34Speaker 1: compliance with notice and comment requirements, and are otherwise arbitrary, capricious,
- 5:40Speaker 1: and abusive discretion and contrary to law. You got everything
- 5:43Speaker 1: in there. Did they not have notice and comment on these?
- 5:46Speaker 2: Well, they actually did have notice in comment and it
- 5:49Speaker 2: was quite quite a long and detailed notice in common procedure.
- 5:54Speaker 2: What the industry is complaining about in that particular section
- 5:57Speaker 2: is that the final rules that were adopted by the
- 6:01Speaker 2: SEC are so different than what was originally proposed. Is that,
- 6:06Speaker 2: in effect that the notice in common period was not sufficient,
- 6:10Speaker 2: and they're arguing in the industry that once the Commission
- 6:13Speaker 2: changed the rules to such a great extent they should
- 6:15Speaker 2: have undergone another notice in common period so that the
- 6:19Speaker 2: industry and others could comment on these new proposed rules
- 6:23Speaker 2: and hopefully convince the SEC to roll them back even further.
- 6:28Speaker 1: Drew Maloney, chief executive the American Investment Council, to all
- 6:33Speaker 1: the Wall Street Journal that the rules will discourage competition,
- 6:37Speaker 1: harm investors, reduce returns, stifle innovation, and impose costly burdens
- 6:42Speaker 1: on funds of all sizes. Do you agree with any
- 6:45Speaker 1: of that?
- 6:46Speaker 2: Well, I do. I think that there's no question that
- 6:49Speaker 2: the rules themselves are going to be quite costly. Even
- 6:52Speaker 2: in the adopting release, it's acknowledged by the SEC that
- 6:55Speaker 2: it's going to cost billions of dollars industry wide to
- 6:59Speaker 2: comply with the rule. In the argument is that this
- 7:02Speaker 2: really falls most heavily on the small advisors or new
- 7:06Speaker 2: advisors that want to come into the space, and essentially
- 7:09Speaker 2: the costs associated with compliance is going to be prohibitive.
- 7:14Speaker 2: But I think, you know, one of the main points
- 7:17Speaker 2: of the industry too, is that it really questions the
- 7:19Speaker 2: role of the SEC in the sense that for years,
- 7:23Speaker 2: the industry, which is made up of these institutional investors
- 7:26Speaker 2: that are very sophisticated and private fund managers have been
- 7:30Speaker 2: going along fine in terms of negotiating contract provisions that
- 7:34Speaker 2: were customized to their own individual and situations that were
- 7:38Speaker 2: structured in that in that way, and the SEC has
- 7:42Speaker 2: now stepped into the picture and said, you know, no, no,
- 7:45Speaker 2: you know, we know better as the SEC what contractual
- 7:49Speaker 2: terms should be in place, and the contractual terms that
- 7:52Speaker 2: you've been negotiating all along though, those are no longer
- 7:55Speaker 2: going to be permitted because you know, we have decided
- 7:58Speaker 2: to fundamentally change the way this market is regulated. And
- 8:02Speaker 2: the industry is saying that the SEC has no statutory
- 8:05Speaker 2: authority from Congress to step in and make that unilateral determination.
- 8:10Speaker 1: SEC chair Gary Gansler said he feels very confident in
- 8:16Speaker 1: the agency's conclusion that it does have the power to
- 8:19Speaker 1: implement the rules. What's your take on it. Does it
- 8:22Speaker 1: have the power?
- 8:23Speaker 2: I think that's going to be a tough argument for
- 8:25Speaker 2: the SEC. The industry challenged the rules in the Fifth Circuit,
- 8:29Speaker 2: which historically has been somewhat hostile to the SEC's expansive
- 8:34Speaker 2: claims of regulatory authority. So the industry, you know, made
- 8:39Speaker 2: a smart decision in terms of the forum that they've
- 8:41Speaker 2: decided to challenge these rules, and in the adopting release,
- 8:45Speaker 2: the SEC really just pointed to some very general provisions,
- 8:49Speaker 2: you know, the anti fraud provision is one basis, and
- 8:53Speaker 2: another provisions that related to requiring the SEC to provide
- 8:58Speaker 2: enhanced rulemaking so that advisors would have to be clear
- 9:02Speaker 2: about the terms and conditions of their relationship with investors,
- 9:06Speaker 2: which was contained in the retail regulation section of DoD
- 9:10Speaker 2: Frank And traditionally, federal courts in the last several years
- 9:13Speaker 2: have been hostile not only to the SEC, but to
- 9:16Speaker 2: other agencies who claim these broad ranging powers to regulate
- 9:21Speaker 2: industries that in a lot of respects are hard hard
- 9:24Speaker 2: to tie into the congressional grants of authority that have
- 9:27Speaker 2: been made to the agencies.
- 9:29Speaker 1: Coming up next, I'll continue this conversation with Robert him
- 9:33Speaker 1: and we'll talk more about why this suit was filed
- 9:36Speaker 1: at the Fifth Circuit. Lawsuits challenging the SEC rules are
- 9:40Speaker 1: filed directly to appeals court, so they skipped the lower
- 9:44Speaker 1: district court and they went to the Fifth Circuit, as
- 9:48Speaker 1: you mentioned, which is the go to venue for conservatives
- 9:51Speaker 1: and business groups challenging regulatory authority and ranging from the
- 9:56Speaker 1: abortion pill, which is still in litigation the SEC's in
- 10:01Speaker 1: house courts.
- 10:02Speaker 2: Yes, that's correct. You know, the Fifth Circuit in particular
- 10:06Speaker 2: has been very open to constitutional based arguments from business
- 10:11Speaker 2: groups and private parties to really look at what agencies
- 10:15Speaker 2: are doing to make sure that it's it's constrained within
- 10:18Speaker 2: their statutory authority. And this is really a fundamental principle
- 10:22Speaker 2: in the Constitution in terms of you know, in the
- 10:25Speaker 2: democracy are elected representatives in Congress are supposed to make
- 10:30Speaker 2: laws that people can vote on, and then there's a
- 10:33Speaker 2: narrow delegation to agencies to implement those laws. But here,
- 10:38Speaker 2: for example, with the SEC's regulation of the industry, and
- 10:41Speaker 2: these new rules really didn't go through a democratic process.
- 10:45Speaker 2: It was just something that the agency decided, you know,
- 10:48Speaker 2: in their view, needed to be done and impose these rules.
- 10:52Speaker 2: And then that's the argument from the industry. We're We're
- 10:54Speaker 2: going to have to see if the judges in the
- 10:56Speaker 2: Fifth Circuit accept that, and that's going to be their
- 10:59Speaker 2: decision as to whether or not these SEC rules come
- 11:02Speaker 2: within the statutory authority. And the Investment Advisors Act to
- 11:06Speaker 2: allow the SEC to implement these sort of changes and rules.
- 11:10Speaker 1: It's been sort of a regulatory blitz by SEC Chair
- 11:14Speaker 1: Gary Gensler that we've talked about before. Is this just
- 11:19Speaker 1: one step too far?
- 11:21Speaker 2: Yeah, I think that that's part of the analysis. One
- 11:24Speaker 2: of the concerns that Commissioner Peerce had that the industry
- 11:27Speaker 2: has as well, is that when the SEC conducts its
- 11:32Speaker 2: statutorily require cost benefit analysis of the new rules, they
- 11:36Speaker 2: look at each rule one by one and they say,
- 11:39Speaker 2: what's the cost and the benefits of this particular rule
- 11:42Speaker 2: on the industry. But the point that the industry is
- 11:45Speaker 2: making is that that's not always the best way to
- 11:47Speaker 2: look at this, because the SEC has been engaged in
- 11:51Speaker 2: a lot of new rule making. It seems like every
- 11:54Speaker 2: week there's a new rule that comes out, and the
- 11:56Speaker 2: industry is saying that it's not sufficient just to look
- 11:59Speaker 2: one by one.
- 12:00Speaker 3: Really have to look at the.
- 12:01Speaker 2: Whole basket of rules that the SEC is coming out
- 12:04Speaker 2: with in lots of different areas, when you look at
- 12:06Speaker 2: this sort of costs that are being imposed on the
- 12:09Speaker 2: private sector and whether the rules are really going to
- 12:12Speaker 2: provide the investor protection benefits that the SEC claims that
- 12:16Speaker 2: they are working towards.
- 12:18Speaker 1: Are these cases different in that this is a really
- 12:22Speaker 1: wealthy and powerful industry that the SEC is going up against.
- 12:27Speaker 2: Well, it does make a difference in a sense that
- 12:30Speaker 2: the challenge to these rules is certainly a well funded effort.
- 12:35Speaker 2: The lead lawyer Jean Scalia, who's the son of Justice Scalia,
- 12:40Speaker 2: the lead Justice Scalia, is probably the top lawyer that
- 12:44Speaker 2: the industry is used to challenge various regulations, not just
- 12:48Speaker 2: at the SEC, but at the EPA as well on
- 12:51Speaker 2: the argument that the rules exceed statutory grants of authority.
- 12:56Speaker 2: But I think it's also a more fundamental point. The
- 12:59Speaker 2: industry is arguing that Congress deliberately set up a two
- 13:02Speaker 2: part regulatory system. One is mutual funds, which are regulated
- 13:08Speaker 2: under the Investment Company Act, which has extensive disclosures and
- 13:12Speaker 2: substantive rules that are appropriately in place to protect private
- 13:16Speaker 2: retail investors. And Congress made a conscious decision to not
- 13:22Speaker 2: impose that extensive regulatory regime on private funds which are
- 13:26Speaker 2: opened only to a very high net worth investors and
- 13:30Speaker 2: institutional investors. And Congress basically left it up to the
- 13:34Speaker 2: parties in that scenario to negotiate contractual arrangements regarding fees
- 13:41Speaker 2: regarding investment objectives and what duties the advisor owes and
- 13:45Speaker 2: what the SEC has done with these rules is blur
- 13:49Speaker 2: the distinction between those two regulatory regimes and is really
- 13:53Speaker 2: importing these extensive regulations from the mutual fund space onto
- 13:57Speaker 2: the private fund space. And a lot of respect, if there's.
- 14:01Speaker 1: An adverse ruling to the SEC, does that have implications
- 14:05Speaker 1: for other areas the SEC is regulating.
- 14:09Speaker 2: It won't have a direct implication for other rules that
- 14:12Speaker 2: the SEC is making, but in a certain sense, it
- 14:16Speaker 2: really from a practical perspective, makes the agency sit up
- 14:20Speaker 2: and take notice, to really understand that courts are going
- 14:24Speaker 2: to be scrutinizing their claims of statutory authority and perhaps
- 14:28Speaker 2: gives the SEC more reason to pause it's rulemaking and
- 14:32Speaker 2: not be so aggressive in the future with regards to
- 14:36Speaker 2: the type of rules and changes that it imposes on
- 14:39Speaker 2: the industry.
- 14:41Speaker 1: Bob was the SEC sort of prepared for this lawsuit?
- 14:44Speaker 2: The SEC really understood that they were going to have
- 14:48Speaker 2: a challenge of these rules in court, and the adopting
- 14:51Speaker 2: release has quite an extensive discussion by the SEC as
- 14:56Speaker 2: to what its claims of statutory authority are. In addition
- 15:00Speaker 2: to going through the two satchatory provisions, and the adopting release,
- 15:04Speaker 2: the SEC goes to great lengths to really try to
- 15:07Speaker 2: explain that it's not really just institutional investors that are
- 15:12Speaker 2: at stake here. The adopting release talks about that it's
- 15:16Speaker 2: it's pension funds and endowments, and indirectly those pensions are
- 15:21Speaker 2: made up of civil service workers, environment police officials, teachers,
- 15:26Speaker 2: community activists, and the SEC goes through a whole description
- 15:30Speaker 2: in their adopting release as to how these everyday types
- 15:33Speaker 2: of people are impacted by the private fund industry and
- 15:37Speaker 2: the types of rules and regulations that are imposed on it. So,
- 15:42Speaker 2: you know, the SEC knew that this challenge was coming.
- 15:45Speaker 2: They've done, you know, everything they can to prepare for it.
- 15:48Speaker 2: So it's going to be a very interesting when the
- 15:50Speaker 2: court addresses this. The parties have proposed a timeframe that
- 15:54Speaker 2: would allow the Fifth Circuit to issue ruling by May
- 15:57Speaker 2: twenty twenty four, which is several months before a lot
- 16:01Speaker 2: of the final deadline for when these rules have to
- 16:03Speaker 2: go in effect.
- 16:05Speaker 1: So a long road ahead, Thanks so much, Bob. That's
- 16:08Speaker 1: Robert him of Tartarkrinsky and Drogen. Coming up next on
- 16:12Speaker 1: the Bloomberg law show class action lawsuits against pharmaceutical companies
- 16:17Speaker 1: and retailers over ineffective decongestants. We're approaching cold and flu season,
- 16:24Speaker 1: and the Food and Drug Administration has said the leading
- 16:27Speaker 1: over the counter decongestion used by millions of Americans looking
- 16:31Speaker 1: for relief from a stuffy nose is no more effective
- 16:35Speaker 1: than a placebo. Advisors to the FDA voted unanimously last
- 16:39Speaker 1: week against the effectiveness of the key drug found in
- 16:42Speaker 1: popular versions of sudafed, day quill and other medications stocked
- 16:47Speaker 1: on store shelves.
- 16:49Speaker 4: This ingredient panel affron is in so many different cold medicines.
- 16:54Speaker 4: That's why it is important to kind of educate yourself
- 16:57Speaker 4: on what to look for and just avoid that ingredient.
- 17:00Speaker 1: Doctor Purvy Perik, an allergist at NYU Langone Health, recommends
- 17:05Speaker 1: reading the labels of these products and choosing something else instead.
- 17:09Speaker 1: It didn't take long after the FDA's announcement for several
- 17:13Speaker 1: class action lawsuits to be filed against pharmaceutical companies and retailers.
- 17:19Speaker 1: My guest is healthcare attorney Harry Nelson of Nelson Hardiman
- 17:23Speaker 1: Harry first tell us about this board of advisors and
- 17:27Speaker 1: what they decided.
- 17:29Speaker 3: Yeah, it was an FDA advisory panel that finally came
- 17:32Speaker 3: out with a statement that people studying funnelf've been talking
- 17:35Speaker 3: about for a while, which is that it is not
- 17:38Speaker 3: better than placebo. That essentially it's ineffective when taken orally.
- 17:43Speaker 3: It does not actually function as a decongestine, and little
- 17:47Speaker 3: of the drug actually reaches the nose to be a decongestine.
- 17:50Speaker 3: It's effective when it's used in a nasal pray directly
- 17:54Speaker 3: to the nose. But the problem is that we sell
- 17:56Speaker 3: billions of dollars of these different decongestin drugs where people
- 17:59Speaker 3: take it orally and it has absolutely no effect, was
- 18:01Speaker 3: completely broken down in the stomach.
- 18:03Speaker 1: So you mentioned this, But there have been decades of
- 18:07Speaker 1: studies and questions and documentation and clinical trial results. Why
- 18:12Speaker 1: did it take so long for them to come to
- 18:14Speaker 1: this conclusion.
- 18:17Speaker 3: It's a good question. It's kind of an indictment, honestly,
- 18:20Speaker 3: of the FDA's ability to do serious review. There were
- 18:25Speaker 3: studies being put forward and petitions made to re examine it.
- 18:29Speaker 3: But when you go back and look at what was happening,
- 18:31Speaker 3: you know, for the last twenty plus years, it's been
- 18:33Speaker 3: a process of rubber stamping and ignoring what's been said.
- 18:37Speaker 3: It was a glacial pace, and it took an enormous
- 18:39Speaker 3: amount of time for peer review studies to actually be
- 18:42Speaker 3: given the attention they deserve. So it's kind of an
- 18:44Speaker 3: indictment of the FDA process, you know that it took
- 18:48Speaker 3: this long to see something that was quite obvious to
- 18:51Speaker 3: people who were studying it.
- 18:52Speaker 1: And the decision is confusing to consumers because shouldn't ineffective
- 18:56Speaker 1: drugs be taken off the market and replaced? But here
- 19:00Speaker 1: they're saying, no, you don't need to throw away these products.
- 19:03Speaker 3: No one is saying these products are dangerous or the
- 19:05Speaker 3: penalleffern causes harm. They're just saying it's ineffective. It's not
- 19:09Speaker 3: better than placebo. So there's no danger associated with using
- 19:14Speaker 3: these products. They're probably just not the best choices to use.
- 19:17Speaker 3: You need an effective decongestion.
- 19:20Speaker 1: This is just an advisory opinion. The FDA doesn't have
- 19:24Speaker 1: to go along with it. And now what happens, They're
- 19:27Speaker 1: going to allow the public to comment. What good does
- 19:29Speaker 1: public comment do on an issue like this? I don't
- 19:32Speaker 1: get that.
- 19:33Speaker 3: Yeah. Also, it's a fair question. It's not at all
- 19:35Speaker 3: clear what public comment is going to add to the
- 19:37Speaker 3: conversation here. It just seems like they're still continuing to
- 19:40Speaker 3: go slower than you would hope. Once we've kind of
- 19:43Speaker 3: finally come to this public realization that there's a drug
- 19:46Speaker 3: that's not working on the market and people are spending
- 19:48Speaker 3: a lot of money on it, what does the.
- 19:49Speaker 1: FDA have to do now in addition to you know,
- 19:52Speaker 1: we mentioned the public comments, but what has to happen next.
- 19:55Speaker 3: The next step is actually formal. This was just an
- 19:58Speaker 3: advisory chanel, but the FDA has to formally review the
- 20:02Speaker 3: status of the drug and presumably revoke its approoved status
- 20:06Speaker 3: or narrow its approved status, because again, the drug is
- 20:08Speaker 3: useful when applied directly, for example, like through a nasal spray,
- 20:12Speaker 3: but at least orally to revoke the approval of the drugs.
- 20:16Speaker 1: How unusual is it that class action lawsuits were filed
- 20:21Speaker 1: within days of the FDA's announcement.
- 20:26Speaker 3: So, I mean it's almost reflective, right, There are plaint
- 20:28Speaker 3: of law firms around the countries that are basically built
- 20:31Speaker 3: to take on harm related to different drugs, and so
- 20:35Speaker 3: soon as the FDA said the drug was ineffective, it's
- 20:38Speaker 3: not a surprise that we saw the first class action
- 20:40Speaker 3: filed down in Florida. I'm sure we're going to see more.
- 20:43Speaker 3: The real question is, other than the harm to people's
- 20:46Speaker 3: wallets from spending one point seventy five billion on the drug,
- 20:50Speaker 3: what actual harm? You know, whether there were any side
- 20:53Speaker 3: effects that actually hurt anybody from Fenel effronts. There are
- 20:56Speaker 3: a lot of reports of like minor problems like swelling
- 20:59Speaker 3: or interration and itching, but I'm not aware of any
- 21:03Speaker 3: severe harm, and it's not clear what kind of damages
- 21:06Speaker 3: they are going to be beyond just the fact that
- 21:08Speaker 3: these companies were selling an ineffector drug.
- 21:11Speaker 1: Some of the complaints charged that the defendants violated consumer
- 21:15Speaker 1: protection statutes and alleged a breach of implied warranty of
- 21:20Speaker 1: merchant ability and they committed fraud, stating the defendants intentionally
- 21:24Speaker 1: and knowingly falsely concealed, suppressed, and or admitted material facts,
- 21:29Speaker 1: including us to the standard, quality or grade of the
- 21:32Speaker 1: products they marketed and sold. But if the FDA approved this,
- 21:37Speaker 1: what were the manufacturers supposed to do? Say no, the
- 21:40Speaker 1: FDA is wrong.
- 21:41Speaker 3: You know, there's been a lot of industry studies going on,
- 21:45Speaker 3: so we know that, for example, competitors of some of
- 21:48Speaker 3: the fenleft and products, like the folks that sharing plout
- 21:50Speaker 3: who were making Clereson were doing a lot of research
- 21:53Speaker 3: to show that and arguing that these drugs were ineffective.
- 21:56Speaker 3: It's an interesting question whether internally whether the manu were
- 22:00Speaker 3: doing their own research and had reason to know that
- 22:03Speaker 3: these drugs were not effective, and whether they turned a
- 22:06Speaker 3: blind eye to it. I think it's an interesting question,
- 22:08Speaker 3: and hopefully we'll learn about some of the internal process
- 22:11Speaker 3: within the pharmaceuticals and how much they were aware of
- 22:14Speaker 3: this and taking it seriously and concerned about it. But
- 22:17Speaker 3: you know, I think that still remains ahead of us.
- 22:19Speaker 1: You know, you mentioned harm to consumers and that there's
- 22:22Speaker 1: probably very little of that, so it would be limited
- 22:25Speaker 1: to economic damages, right, I mean, how would they determine
- 22:29Speaker 1: economic damages to consumers from this?
- 22:33Speaker 3: I think what's likely to happen. I mean, I don't
- 22:35Speaker 3: mean to sound cynical, but when this case gets prosecuted,
- 22:38Speaker 3: what's likely to happen is that the lawyers who brought
- 22:40Speaker 3: these cases will have a multimillion dollar pay day and
- 22:43Speaker 3: attorneys fees, and they'll be coupons, you know, for people
- 22:47Speaker 3: who can prove that they bought the drugs, but those
- 22:49Speaker 3: coupons will be for insignificant amounts. The big winners in
- 22:52Speaker 3: this class accent are likely to be the lawyers who
- 22:55Speaker 3: get tens of millions of dollars for filing it.
- 22:57Speaker 1: As an example, Johnson and Johnson's consumer unit settle claims
- 23:02Speaker 1: alleging aerosol products contained benzene for one point seventy five
- 23:07Speaker 1: million dollars plus two point five million in attorneys fees,
- 23:12Speaker 1: So more an attorney's fees than in the settlement for consumers.
- 23:16Speaker 4: Yeah.
- 23:17Speaker 3: So a lot of people, and including me, think it
- 23:19Speaker 3: is a defect in our class action systems that, you know,
- 23:21Speaker 3: the plane of class action lawyers are motivated to bring
- 23:25Speaker 3: cases that really don't do much to advance the public interest,
- 23:28Speaker 3: but to produce profitable work for them. Kind of a
- 23:32Speaker 3: sort of bug in our class action system that anytime
- 23:36Speaker 3: there's a drug, even if the harm to the public
- 23:38Speaker 3: is really miniscule, the plane of class action lawyers have
- 23:40Speaker 3: a big opportunity.
- 23:41Speaker 1: Are those kinds of suits mostly settled? Do any of
- 23:44Speaker 1: them ever go to trial?
- 23:46Speaker 3: This is certainly not a case that's going to trial.
- 23:48Speaker 3: This is clearly you know, if there were big damages
- 23:52Speaker 3: and significant amounts that would be at risk, Like if
- 23:56Speaker 3: the harm caused by a final effort was so significant,
- 23:59Speaker 3: then there would be something to fight over and a
- 24:01Speaker 3: lot at stakes. But you know, the money that the
- 24:04Speaker 3: drug companies are likely to pay for this is going
- 24:07Speaker 3: to be something like a rounding error for them. This
- 24:09Speaker 3: is not going to be one of those multi billion
- 24:11Speaker 3: dollar settlements. You know, it's likely that the plans class
- 24:14Speaker 3: ection layers will kind of have a get in quick,
- 24:16Speaker 3: you know, reach the settlements, and the drug companies will
- 24:19Speaker 3: be offered numbers that will motivate them to do so.
- 24:21Speaker 3: I think it's a pretty safe bet that we're never
- 24:23Speaker 3: going to see a trial on the marketing of fenel efern.
- 24:27Speaker 3: Does the FDA.
- 24:28Speaker 1: Give the drug manufacturers time to put new products on
- 24:33Speaker 1: the shelves or don't they take that into consideration.
- 24:37Speaker 3: The first decision is whether to actually revoke the marketing
- 24:41Speaker 3: approval for it. But if the FDA imposes a recall,
- 24:44Speaker 3: the recall is focused on exclusively on the public health
- 24:47Speaker 3: issues and not on whether these drug companies have time
- 24:52Speaker 3: to find alternatives. That's really the drug companies problems. I'm
- 24:55Speaker 3: sure that the folks at all the companies that we're
- 24:57Speaker 3: selling sele An Efferns are you know, already working hard
- 25:00Speaker 3: on that. But the really interesting question here is whether
- 25:03Speaker 3: the fact that the drug is ineffective, though not seemingly dangerous,
- 25:07Speaker 3: is going to provoke an actual recall or alternatively, whether
- 25:12Speaker 3: presumably its sales will decline. The drug companies will obviously
- 25:15Speaker 3: stop marketing it because you know, now that the FDA
- 25:18Speaker 3: has come out with this, it's a much higher risk
- 25:20Speaker 3: for them to engage in any marketing suggesting that it
- 25:22Speaker 3: has positive benefit, and whether we'll just fade away from
- 25:25Speaker 3: the shelves of our drug stores sort of more naturally.
- 25:27Speaker 1: I sort of assume that the FGA, in light of this,
- 25:31Speaker 1: would take these off the shelves at some point, since
- 25:34Speaker 1: the best you can say is they're ineffective.
- 25:36Speaker 3: Honestly, I think the reason that tenneleffernd became popular in
- 25:40Speaker 3: the first place was because of problems associated with a
- 25:43Speaker 3: different decontestant that is effective, which is a related drug
- 25:47Speaker 3: category called pseudofhedriant. You know, more than fifteen years ago
- 25:50Speaker 3: we started seeing that metam fetamine dealers or manufacturers were
- 25:55Speaker 3: using due to Fedrian to make illegal drugs and so
- 26:00Speaker 3: so that led to the popularity of penalleffern as an alternative.
- 26:04Speaker 3: So I think now it's kind of back to the
- 26:06Speaker 3: drawing board of actually figuring out what are going to
- 26:09Speaker 3: be you know, effective decongestion, And it's going to be
- 26:12Speaker 3: interesting to see what the impact on pseudofedrian access is,
- 26:17Speaker 3: given that it is a ineffective the congestion, but also
- 26:21Speaker 3: a drug that is at risk of a view. That's
- 26:23Speaker 3: a part of the story that we haven't really been
- 26:24Speaker 3: talking about yet. But I think it is clear that
- 26:27Speaker 3: part of the rise of seneffrine was about the problems
- 26:30Speaker 3: associated with pseudophedrin. So it's going to be interesting to
- 26:33Speaker 3: see what medications are the winners after senal eleftferm phades
- 26:37Speaker 3: from the market.
- 26:38Speaker 1: Thanks so much, Harry. That's healthcare attorney Harry Nelson of
- 26:41Speaker 1: Nelson Hardiman